Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Pancreatic Ductal Adenocarcinoma × PEGPH20 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 4 Adenocarcinoma 2 Pancreatic Ductal Adenocarcinoma 1 Neoplasms 1 Carcinoma, Pancreatic Ductal 1

Interventions

titanium silicide 1 mitazalimab 1 devimistat 1 S 1 (combination) 1 PEGPH20 1 Oxaliplatin 1 Irinotecan 1 Gemcitabine 1 Escitalopram 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04134468 2020-01-31

MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma

Abramson Cancer Center at Penn Medicine

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Ductal Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡